Imipramine Pamoate

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Imipramine Pamoate

What is Imipramine Pamoate

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine is a tricyclic antidepressant (TCA) used to treat depression. It works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate mood. It also blocks certain receptors in the body, which can lead to side effects such as sedation, low blood pressure, and blurred vision. Imipramine is also sometimes prescribed to treat conditions such as chronic pain, panic disorder, ADHD, and PTSD.

Tofranil

is the brand name

image of different drug pills on a surface

Imipramine Pamoate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

Effectiveness

How Imipramine Pamoate Affects Patients

Imipramine is a type of antidepressant that helps to treat depression by increasing the levels of serotonin and norepinephrine, two chemicals in the brain that can affect mood. It is similar to other drugs such as amitriptyline and doxepin. When taken, imipramine can lead to changes in the brain such as increased production of nerve cells and reduced stress responses. It is believed that these changes, along with its effect on serotonin, are what make it an effective antidepressant. Additionally, it may cause a decrease in certain receptors in the brain that help to regulate adrenaline.

How Imipramine Pamoate works in the body

Imipramine helps treat depression by blocking the removal of two important neurotransmitters, norepinephrine and serotonin, from the spaces between neurons. This allows these two chemicals to stay in the spaces between neurons longer, stimulating the neurons and relieving symptoms of depression.

When to interrupt dosage

The recommended dosage of Imipramine Pamoate is contingent upon the diagnosed condition, such as Bedwetting, Bulimia Nervosa and Depression. The amount of dosage is dependent on the mode of administration (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral), as indicated in the below table.

Condition

Dosage

Administration

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Warnings

Imipramine Pamoate has two contraindications and should not be concomitantly administered when afflicted with any of the conditions in the table below.

Imipramine Pamoate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Imipramine Pamoate.

Common Imipramine Pamoate Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Imipramine Pamoate Toxicity & Overdose Risk

Taking too much imipramine can cause dryness in the mouth and eyes, increased body temperature, constipation, difficulty urinating, tiredness, agitation, nightmares, confusion, decreased appetite, stomach pain, vomiting, and a strange taste in the mouth. In rare cases, it can lead to low blood cell counts and blood clotting problems. Infants born to mothers taking imipramine may experience heart problems, fussiness, breathing difficulty, muscle spasms, convulsions, and difficulty urinating. Taking it with other drugs that increase serotonin levels can cause serotonin syndrome. The LD50 for rats is 250mg/

image of a doctor in a lab doing drug, clinical research

Imipramine Pamoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Imipramine Pamoate?

779 active clinical trials are currently assessing the potential of Imipramine Pamoate to provide relief from Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

290 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

12 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Imipramine Pamoate Reviews: What are patients saying about Imipramine Pamoate?

4.3

Patient Review

1/16/2014

Imipramine Pamoate for Depression

Imipramine has been extremely effective for me in treating my psychiatric problems. I've been taking it for most of my life, and the imipramine pamoate formulation seems to really help with side effects like tremor and dry mouth. The old tricyclic antidepressants have a similar effect to the newer SNRIs but are much cheaper, so Imipramine is a great option.

4.3

Patient Review

11/19/2013

Imipramine Pamoate for Depression

The side effects of this medication were really terrible and it made my symptoms worse. I was stressed, agitated, and felt strung-out all the time. I took it for off-label use for ADHD and it is by far the worst medication I have ever taken.

2

Patient Review

1/6/2011

Imipramine Pamoate for Depression

I took this medication for its side effect of causing sleep.

1

Patient Review

7/1/2013

Imipramine Pamoate for Attention Deficit Disorder with Hyperactivity

Imipramine has helped me a lot with my incontinence issues.

Patient Q&A Section about imipramine pamoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is imipramine pamoate?

"Imipramine belongs to a class of antidepressants known as tricyclics. It treats depression by increasing the levels of certain chemicals in the brain that are necessary for mental balance."

Answered by AI

What is imipramine pamoate used for?

"This drug is given to people who are suffering from depression. It is thought to work by aiding in the regulation of moods, and may also help with sleep and appetite. It may also give the patient more energy to take part in daily activities. The drug imipramine pamoate is classified as a tricyclic antidepressant."

Answered by AI

What is the difference between Imipramine HCl and pamoate?

"Imipramine HCl is FDA approved for adults and adolescents with depression, as well as bedwetting in children. Imipramine pamoate is only approved to treat depression in adults ages 17 and up."

Answered by AI

Is imipramine used for anxiety?

"Imipramine is a drug that is used to treat depression, anxiety, and panic disorder. It belongs to a class of drugs called tricyclic antidepressants. It is often used to treat bedwetting in children, even though it is not clear how it prevents bedwetting."

Answered by AI

Clinical Trials for Imipramine Pamoate

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials